CYP2C19型
药代动力学
雷贝拉唑
药效学
药理学
质子抑制剂泵
医学
基因型
胃酸
奥美拉唑
内科学
化学
胃
新陈代谢
生物化学
基因
细胞色素P450
作者
He-Jian Zhang,Xuehui Zhang,Jie Liu,Liang Sun,Yiwen Shen,Chen Zhou,Hongwen Zhang,Ling Xie,Juan Chen,Yun Liu,Yongqing Wang
标识
DOI:10.1016/j.phrs.2019.104606
摘要
Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders. Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics of PPIs are affected by each patient’s CYP2C19 and gastric H+,K+-ATPase genotype. The aim of this review was to analyze the effect of genetic polymorphisms on the pharmacodynamic and pharmacokinetic properties of PPIs. The gastric acid-suppressive effect of PPIs is affected by both gastric H+,K+-ATPase and CYP2C19 polymorphisms, although gastric H+,K+-ATPase polymorphisms may have larger effects. Ilaprazole and rabeprazole show relatively small differences in the pharmacokinetic and pharmacodynamic properties and clinical efficacy among the different CYP2C19 genotypes. Compared with oral administration, the intravenous infusion of PPIs is less affected by CYP2C19 polymorphism. At the same dose, each enantiomer has less variation among different CYP2C19 genotypes than a racemate mixture.
科研通智能强力驱动
Strongly Powered by AbleSci AI